ATE342509T1 - Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau - Google Patents

Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau

Info

Publication number
ATE342509T1
ATE342509T1 AT01909655T AT01909655T ATE342509T1 AT E342509 T1 ATE342509 T1 AT E342509T1 AT 01909655 T AT01909655 T AT 01909655T AT 01909655 T AT01909655 T AT 01909655T AT E342509 T1 ATE342509 T1 AT E342509T1
Authority
AT
Austria
Prior art keywords
tau
phospho
diagnosis
tauopathies
ratio
Prior art date
Application number
AT01909655T
Other languages
English (en)
Inventor
Eugeen Vanmechelen
Hugo Vanderstichele
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE342509T1 publication Critical patent/ATE342509T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
AT01909655T 2000-01-24 2001-01-18 Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau ATE342509T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00870008 2000-01-24
US17839100P 2000-01-27 2000-01-27
EP00870280 2000-11-22

Publications (1)

Publication Number Publication Date
ATE342509T1 true ATE342509T1 (de) 2006-11-15

Family

ID=27223742

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01909655T ATE342509T1 (de) 2000-01-24 2001-01-18 Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau

Country Status (13)

Country Link
US (2) US6680173B2 (de)
EP (1) EP1250600B1 (de)
JP (1) JP5247963B2 (de)
AT (1) ATE342509T1 (de)
AU (1) AU777837B2 (de)
BR (1) BR0107851A (de)
CA (1) CA2397991C (de)
CY (1) CY1107993T1 (de)
DE (2) DE60123752T2 (de)
DK (1) DK1250600T3 (de)
ES (1) ES2274869T3 (de)
HK (1) HK1048513B (de)
WO (1) WO2001055725A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
JP4681175B2 (ja) * 2001-09-28 2011-05-11 三菱化学メディエンス株式会社 播種性血管内凝固症候群及びその発症前段階を検出する方法
EP1535930B1 (de) * 2002-08-14 2010-10-06 Mitsubishi Chemical Medience Corporation Antikörper spezifisch für das tau-protein des zentralen nervensystems
WO2004081534A2 (en) * 2003-03-12 2004-09-23 Assay Designs, Inc. Phosphokinase assay
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
WO2005080986A1 (en) * 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
JP4730584B2 (ja) 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
WO2007068105A1 (en) * 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
CA2725143A1 (en) * 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
EP2480891B1 (de) 2009-09-24 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Fkbp52-tau-interaktion als neuartiges therapeutisches target zur behandlung von neurologischen erkrankungen im zusammenhang mit tau-störungen
US20130095492A1 (en) * 2010-03-05 2013-04-18 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
US20130052669A1 (en) * 2010-04-30 2013-02-28 Amanda G. Paulovich Compositions and methods for reliably detecting and/or measuring the amount of a modified target protein in a sample
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
MX359817B (es) 2012-08-16 2018-10-11 Ipierian Inc Anticuerpos que se enlazan a tau.
EP2893042B1 (de) * 2012-09-05 2018-02-14 Emory University Diagnostische tests bei demenz und zugehörige verfahren
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
PL3007726T3 (pl) 2013-06-10 2021-01-11 Ipierian, Inc. Metody leczenia tauopatii
PL3083680T3 (pl) 2013-12-20 2020-06-29 F. Hoffmann-La Roche Ag Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
AU2015243926A1 (en) * 2014-04-08 2016-11-24 The Research Foundation For The State University Of New York Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
DE102014013571A1 (de) * 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoklonaler Antikörper gegen humanes TAU-Protein
EP3313877B1 (de) 2015-06-24 2020-06-03 H. Hoffnabb-La Roche Ag Humanisierte anti-tau(ps422)-antikörper und verfahren zur verwendung
KR102033776B1 (ko) * 2017-10-31 2019-10-17 가천대학교 산학협력단 타우 단백질의 발현수준을 측정하는 제제를 포함하는 알츠하이머 중증도 진단용 조성물 및 이를 이용한 알츠하이머 중증도의 진단방법
CN112105639A (zh) * 2018-03-05 2020-12-18 詹森药业有限公司 抗PHF-tau抗体及其用途
CN113166235A (zh) * 2018-11-22 2021-07-23 富士瑞必欧株式会社 抗体偶联物
US20220187322A1 (en) * 2019-03-28 2022-06-16 H. Lundbeck A/S Use of a ps396 assay to diagnose tauophaties
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
WO2020242963A1 (en) * 2019-05-31 2020-12-03 Eli Lilly And Company Compounds and methods targeting human tau
WO2021157634A1 (ja) * 2020-02-05 2021-08-12 大日本住友製薬株式会社 タウオパチーおよび認知症関連疾患の判定薬および判定方法
TW202344840A (zh) * 2022-01-12 2023-11-16 英商Ｇｔ創新公司 診斷檢定

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600951A4 (en) * 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
US5843779A (en) * 1992-12-14 1998-12-01 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, and hybridomas secreting these antibodies
JPH06239899A (ja) * 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
EP0737208B1 (de) * 1993-12-21 2006-08-02 Innogenetics N.V. Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen
AU710952B2 (en) * 1994-07-29 1999-09-30 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
WO1997034145A1 (fr) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1999062548A1 (en) * 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies

Also Published As

Publication number Publication date
US20030194742A1 (en) 2003-10-16
DE1250600T1 (de) 2003-03-06
BR0107851A (pt) 2002-10-29
DE60123752T2 (de) 2007-08-23
ES2274869T3 (es) 2007-06-01
CA2397991A1 (en) 2001-08-02
CA2397991C (en) 2017-10-24
JP2003521499A (ja) 2003-07-15
DK1250600T3 (da) 2007-02-05
CY1107993T1 (el) 2013-09-04
AU3731901A (en) 2001-08-07
JP5247963B2 (ja) 2013-07-24
EP1250600A2 (de) 2002-10-23
WO2001055725A2 (en) 2001-08-02
HK1048513B (zh) 2007-12-07
US6680173B2 (en) 2004-01-20
US20040091942A1 (en) 2004-05-13
DE60123752D1 (de) 2006-11-23
HK1048513A1 (en) 2003-04-04
EP1250600B1 (de) 2006-10-11
US7387879B2 (en) 2008-06-17
AU777837B2 (en) 2004-11-04
WO2001055725A3 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
ATE342509T1 (de) Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau
NO973444D0 (no) Fremgangsmåter og forbindelser for magnetrelaksometrisk påvisning av analytter, samt anvendelse av slike
WO2002027326A3 (en) Method and kit for the transderaml determination of analyte concentration in blood
WO2003008933A3 (en) Test strip for a lateral flow assay
ATE312349T1 (de) Differentielle diagnose von neurodegeneration
BR9710836A (pt) Ensaio de analitos usando marcas em partìculas
EP1099102A4 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
ATE406578T1 (de) Candida-nachweis
ITTO20010411A0 (it) Metodo e dispositivo per l'esecuzione di test e saggi ad alta processivita' ed alto valore biologico su cellule e/o composti.
WO2002046746A3 (en) Method for detection of vitamin d metabolites
SE0400191D0 (sv) A test kit for detecting periodontal disease
ATE540319T1 (de) Verfahren für die bestimmung von fk506
DE60117592D1 (de) Diagnose von pre-eclampsia
KR950018482A (ko) 혈소판 응집 측정방법
WO2004094675A3 (en) Compositions and methods for determining the presence of sars coronavirus in a sample
ES2068599T3 (es) Procedimiento de reduccion de interferencias en un dosificado por fluorescencia.
WO2003084384A3 (en) Diagnosis of flavivirus infection
FI20011168A0 (fi) Menetelmä infektion laadun määrittämiseksi
WO2000026251A3 (en) A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
WO2002059600A3 (en) Analyte detection
WO2004029216A3 (en) Diagnosis of invasive mold infection
DE60236849D1 (de) Diagnose von atherosclerose
DE60126991D1 (de) Verfahren ZUR DIAGNOSE VON SCHIZOPHRENIE
EP1731913A3 (de) Verfahren und Zusammensetzungen zur Bestimmung des Lipidperoxidierungsgehaltes in oxidativen Stress-Syndromen und Krankheiten
DE69912453D1 (de) Verfahren und materialien zur diagnose instabiler angina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1250600

Country of ref document: EP